Mesoblast (NASDAQ:MESO) Rating Increased to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Mesoblast (NASDAQ:MESO) to a strong-buy rating in a report published on Monday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Mesoblast’s FY2025 earnings at ($0.71) EPS.

A number of other research analysts have also recently commented on MESO. Piper Sandler restated an “overweight” rating and set a $24.00 price target (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Stock Performance

Shares of NASDAQ MESO opened at $11.82 on Monday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast has a 1 year low of $4.60 and a 1 year high of $22.00. The company’s 50-day moving average is $15.97 and its 200 day moving average is $13.28.

Institutional Investors Weigh In On Mesoblast

Several hedge funds have recently added to or reduced their stakes in MESO. Strategic Financial Concepts LLC bought a new stake in Mesoblast in the 4th quarter worth about $2,744,000. Jane Street Group LLC raised its holdings in shares of Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares during the last quarter. Clayton Financial Group LLC bought a new position in Mesoblast during the fourth quarter valued at approximately $275,000. Oaktree Capital Management LP bought a new stake in shares of Mesoblast during the 4th quarter valued at $3,556,000. Finally, Oaktree Fund Advisors LLC bought a new position in Mesoblast in the 4th quarter worth $949,000. 1.43% of the stock is owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.